Courses

Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and M. Patricia Rivera, will first provide a review of current science in non-small cell lung cancer (NSCLC), including trends in stage distribution of lung cancer. Following, current data for targeted therapies as well as immunotherapies in various ...
View Course
Advances in Nontuberculous Mycobacterial Lung Disease: Improvement in Diagnosis, Treatment and Patient Quality of Life

Advances in Nontuberculous Mycobacterial Lung Disease: Improvement in Diagnosis, Treatment and Patient Quality of Life

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and Charles L. Daley, will first highlight the prevalence and risk factors of nontuberculous mycobacterial lung disease (NTM-LD), as well as the importance of early diagnosis. Following, current criteria and treatment recommendations will be reviewed in the context ...
View Course
The Health-System Pharmacist’s Role in Providing the Most Effective Treatment for Patients with Hepatorenal Syndrome

The Health-System Pharmacist’s Role in Providing the Most Effective Treatment for Patients with Hepatorenal Syndrome

This continuing education activity will highlight the health-system pharmacist’s role in providing treatment for patients with hepatorenal syndrome (HRS). The expert faculty will review the science, pathophysiology, and interplay between vasoconstrictor and vasodilator systems on the renal circulation in patients with hepatorenal syndrome type 1. Real-world data for new and emerging therapeutics in hospitalized patients with HRS type 1, including ...
View Course
Scientific Updates to Improve Outcomes in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Scientific Updates to Improve Outcomes in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

This CME activity, derived from content presented at Maui Derm for Dermatologists 2021, will highlight recent advances in the treatment and management of moderate-to-severe atopic dermatitis, particularly in the adult patient population. The expert faculty, Drs. Jonathan Silverberg and Eric Simpson, will first review the immunopathology of atopic dermatitis, as well as current guidelines for both adolescents and adults. Recent ...
View Course
Clinical Updates for the Management of Patients with Pulmonary Arterial Hypertension

Clinical Updates for the Management of Patients with Pulmonary Arterial Hypertension

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and James R. Klinger, will discuss the overall approach to treatment of pulmonary arterial hypertension (PAH), considering diagnosis, patient characterization, treatment algorithms and patient response. Topics such as the history of pulmonary arterial hypertension, challenges of early diagnosis ...
View Course
Novel Therapeutic Advances to Improve Outcomes in Patients with Tenosynovial Giant Cell Tumor

Novel Therapeutic Advances to Improve Outcomes in Patients with Tenosynovial Giant Cell Tumor

This continuing medical education series includes three, 30-minute serialized, educational interviews, designed to bring clinicians up to date on novel therapeutic advances to improve outcomes in patients with tenosynovial giant cell tumor (TGCT). Tenosynovial giant cell tumor is a rare tumor that often leads to severe morbidity or functional limitations. TGCT is categorized into two subtypes, localized and diffuse, where ...
View Course
Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Antiplatelet therapy is an essential part of secondary prevention of cardiovascular events.  In particular, dual antiplatelet therapy (DAPT) — the combination of aspirin with an oral P2Y12 receptor antagonist — is the predominant approach in patients with acute coronary syndromes (ACS), coronary-artery stenting, or previous myocardial infarction (MI). The three oral P2Y12 receptor antagonists that are in use are clopidogrel, ...
View Course
Therapeutic Advances for the Management of Pediatric Patients with Atopic Dermatitis

Therapeutic Advances for the Management of Pediatric Patients with Atopic Dermatitis

This continuing medical education program is derived from material presented in an AcademicCME-sponsored symposium held in conjunction with the 2020 AAP Virtual National Conference & Exhibition. This continuing medical education program will highlight therapeutic advances for the management of patients with atopic dermatitis, focusing primarily on the pediatric population. The expert faculty, chaired by Dr. Lawrence F. Eichenfield, will first ...
View Course
The Science and Guidelines Concerning COVID-19 and Biosimilar Therapeutics for Inflammatory Conditions

The Science and Guidelines Concerning COVID-19 and Biosimilar Therapeutics for Inflammatory Conditions

In this module, Rowena Schwartz PharmD, BCOP, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair, will provide current data for treating patients with biosimilars in the era of the COVID-19 pandemic. The expert faculty will highlight the evolving impact of COVID-19 on healthcare expenditure, including availability of services and financial burdens. Therapeutic considerations amidst the pandemic will be ...
View Course
Incorporating Biosimilars into Treatment Plans for Inflammatory Rheumatological Disorders

Incorporating Biosimilars into Treatment Plans for Inflammatory Rheumatological Disorders

In this module, Jonathan Kay, MD, along with Beth Faiman, PhD, MSN, APN-BC, AOCN, course chair and Francis A. Farraye, MD, MSc, will review current clinical trial data, including registry data, of biosimilar therapeutics in patients with rheumatological disorders. The expert faculty will analyze recent studies, debating the clinical implications of each. Terms such as biosimilarity, changing and switching will ...
View Course
Loading...